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Supplemental Table 1 Scheme S1. Synthesis of 3 from 1,11-dichloro-3,6,9-trioxa-undecane 1,11-diazido-3,6-9-trioxaundecane (6): To a solution of 1,11-dichloro-3,6,9-trioxa-undecane (1.0 mL, 6.3 mmol) in 15 mL DMF was added sodium azide (1.3 g, 20 mmol). The reaction was heated to 70°C and allowed to stir overnight under nitrogen. After 16 h, the reaction mixture was diluted with 150 mL water and extracted three times with diethyl ether (3x 50 mL). The combined organic layers were washed three times with water (3x 10 mL), and dried over Mg 2 SO 4 . Filtration and concentration gave 1.1 g of the product as a yellow oil (72% yield 1,11-diamino-3,6,9-trioxaundecane (7): Ethanol (100 mL) was used to dissolve 6 (1.1 g, 4.4 mmol) and the solution was transferred to a hydrogenator flask. A catalytical amount of 10 wt % Pd/C was added and the vessel shaken on a hydrogenator reactor overnight under 3 atm of H 2 .
Complete reduction of the azide functional group was confirmed with 1 H NMR. The reaction mixture was filtered through Celite, rinsing with 100 mL of methanol. The solvent was removed from the filtrate to yield the product as 505 mg of a yellow oil (62% yield 1-Boc-amine-11-amino-3,6,9-trioxaundecane (8): Dichloromethane (50 mL) was used to dissolve 7 (1.09, 5.7 mmol). After chilling the reaction on ice for 30 minutes, a solution of ditert-butyl dicarbonate (0.53 g, 2.43 mmol) in 25 mL DCM was added. The reaction was left to stir for 1 hr at 0° C and 18 hr at room temperature. The organic phase was washed four times with 0.5 M NaOH (50 mL) and the organic layer was dried with Mg 2 SO 4 . Filtration and concentration gave 365 mg of the product as a yellow oil (23% yield). 1 H NMR (500 MHz, CDCl 3 ) δ 1.47 (s, 9H), 2.90 (t, J=5.2, 2H), 3.28 (m, 2H), 3.57 (m, 4H), 3.66 (m, 8H).
13 C NMR (126 MHz, CDCl 3 ) δ 28. 8, 40.5, 42.2, 70.4, 70.5, 70.7, 70.9, 79.4, 156.4 3, 29.24, 29.74, 26.23, 39.14, 40.36, 69.98, 70.18, 70.24, 74.04, 77.68, 78.59, 81.33, 82.70, 117.2, 117.66, 138.12, 156.00, 162.33, 172.92 13 C NMR (126 MHz, CDCl 3 ) δ 22. 35, 29.65, 36.20, 39.17, 41.19, 70.03, 70.41, 71.63, 74.15, 77.80, 78.55, 81.32, 82.81, 117.05, 117.61, 138.10, 162.33, 173.58 The solvent was removed by lyophilization and the product was purified by reverse phase HPLC S4 using a C18 column, held at 5% for 5 minutes and eluting with a gradient of 5% -15% acetonitrile in pH 10.38 buffered water over 11 min, t r = 15.1 min. This gave 120 mg of the product as a white solid (45% yield). The purity and identity of the product was confirmed using analytical HPLC-MS on a C18 column, held at 5% for 5 minutes and eluting with a gradient of 5%-30% acetonitrile in water, over 30 min, 
4-(2-{4-[(4-isothiocyanatophenyl)oxy]-7-[3,3-dimethyl-1-(4-sulfonatobutyl)indolin-2-ylidene ]-3,5-(propane-1,3-diyl)-1,3,5-heptatrien-1-yl}-3,3-dimethyl-3H-indolio)butanesulfonate (5):
To a slurry of 33 mg of NaH (60% in mineral oil, 0.85 mmol) and 20 mL anhydrous DMF, under N 2 , was added 12 (60 mg, 0.39 mmol) over ice. After 30 minutes, the reaction was allowed to warm to room temperature and IR-783 (102 mg, 0.136 mg) was added. The reaction was left overnight under N 2. The solvent was removed in vacuo, keeping the water bath temperature below 40°C, and the product was purified by column chromatography using a gradient of 10-30% methanol: dichloromethane. This afforded 100 mg of the product as a dark purple solid (87% yield). 1 H NMR (500 MHz, Methanol-d 4 ) δ 1.40 (s, 12H), 1.94 (s, 8H), 2.07 (m, 2H), 2.79 (t, J = 6.1 Hz, 4H), 2.90 (t, J = 7.0 Hz, 4H), 4.16 (s, 4H), 6.24 (d, J = 14.1 Hz, 2H), 7.21 (s, 4H), 7.38 (m, 9H), 7.94 (d, J = 14.1 Hz, 2H) . 13 C NMR (126 MHz, MeOD) δ 20.97, 22.18, 23.81, 25.83, 26.78, 43.49, 48.91, 50.38, 100.02, 110.78, 115.91, 121.76, 121.90, 125.39, 127.46, 128.42, 135.29, 140.95, 141.64, 142.07, 158.64, 163.01, 172.60 Figure S7 . Toxicity of 1-3 was determined using a luminescent-based cell viability assay. MCF7 cells incubated with concentrations of 1-3 ranging from 0 -100 µM showed ≥ 90% viability. Error bars represent the standard deviation of triplicate experiments. Figure S8 . Cell viability was confirmed using microcapillary flow cytometry. MCF7 cells incubated with 6 -50 µM 1-3 showed no significant decrease in viability. Error bars represent the standard deviation of triplicate experiments. Figure S9 . Time-dependent uptake of complexes 1 and 2 incubated at 20 µM with MCF7 cells. These data show a time-dependent increase in cell uptake. Based on these results, an incubation time of 24 hours was chosen for subsequent experiments to maximize labeling. Figure S10 . Biodistribution of 1 was determined 2, 4, 24, and 48 hours post-i.p. injection in tumor bearing nude mice. The heart, lungs, ovaries, uterus, tumor, muscle, kidneys, liver, and intestines were harvested and imaged ex vivo with near-IR fluorescence imaging. These data show that the most significant accumulation of 1 occurs in the liver and intestines followed by the kidneys, tumor, and uterus. Over time, fluorescence signal decreases in each organ suggesting clearance of the complex. A: all organs, B: organs with lower accumulation of 1, C: organs with greatest accumulation of 1.
